Abstract：Objective To investigate the effect of triggering receptor expressed on myeloid cells 2 (TREM-2) overexpression on airway inflammation and remodeling in mice with asthma. Methods A total of 40 BALB/c mice were randomly divided into normal control, asthma, empty vector, and TREM-2 overexpression groups (n=10 each). Ovalbumin (OVA) sensitization and challenge were performed to establish the model of asthma. The mice in the control group were given normal saline, and those in the empty vector and TREM-2 overexpression groups were transfected with adenovirus vector and TREM-2 adenovirus, respectively. RT-PCR and Western blot were used to measure the expression of TREM-2, MMP-2, MMP-9, ADAM33, and ADAM8. Bronchoalveolar lavage fluid (BALF) was collected to perform cell counting and classification. ELISA was used to measure the total serum level of IgE and the levels of cytokines in BALF. Results Compared with the control group, the asthma group showed significant reductions in the mRNA and protein expression of TREM-2 (P < 0.05), a significantly increased level of Th2 cytokine (P < 0.05), and significantly increased numbers of total cells and classified cells. Compared with the asthma group, the TREM-2 overexpression group showed a significantly reduced level of Th2 cytokine (P < 0.05), a significantly reduced level of IgE (P < 0.05), and significantly reduced numbers of total cells and classified cells (P < 0.05), as well as significantly downregulated expression of the inflammatory factors and growth factors MMP-2, MMP-9, TGF-β1, ADAM8, and ADAM33 (P < 0.05). Conclusions TREM-2 overexpression significantly alleviates airway inflammation and airway remodeling in mice with asthma and may become a potential target for the prevention and treatment of childhood asthma.
WANG Zhen,WANG Jing,ZHANG Wen. Effect of triggering receptor expressed on myeloid cells 2 overexpression on airway inflammation and remodeling in mice with allergic asthma[J]. CJCP, 2016, 18(9): 879-884.
Lazarus SC. Inflammation, inflammatory mediators, and mediator antagonists in asthma[J]. J Clin Pharmacol, 1998, 38(7):577-582.
[2]
Bouchon A, Dietrich J, Colonna M. Cutting edge:inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes[J]. J Immunol, 2000, 164(10):4991-4995.
[3]
Bleharski JR, Kiessler V, Buonsanti C, et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response[J]. J Immunol, 2003, 170(7):3812-3818.
[4]
Jiang H, Xie Y, Abel PW, et al. Regulator of G-protein signaling 2 repression exacerbates airway hyper-responsiveness and remodeling in asthma[J]. Am J Respir Cell Mol Biol, 2015, 53(1):42-49.
Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma[J]. Front Microbiol, 2013, 4:263.
[8]
Prieto J, Van Der Ploeg I, Roquet A, et al. Cytokine mRNA expression in patients with mild allergic asthma following low dose or cumulative dose allergen provocation[J]. Clin Exp Allergy, 2001, 31(5):791-800.
[9]
Ohbayashi H, Shimokata K. Matrix metalloproteinase-9 and airway remodeling in asthma[J]. Curr Drug Targets, 2005, 4(2):177-181.
[10]
Yang YC, Zhang N, Van Crombruggen K, et al. Transforming growth factor-beta1 in inflammatory airway disease:a key for understanding inflammation and remodeling[J]. Allergy, 2012, 67(10):1193-1202.
[11]
Xiong YY, Wang JS, Wu FH, et al. The effects of (±)-Praeruptorin A on airway inflammation, remodeling and transforming growth factor-β1/Smad signaling pathway in a murine model of allergic asthma[J]. Int Immunopharmacol, 2012, 14(4):392-400.
[12]
Knolle MD, Owen CA. ADAM8:a new therapeutic target for asthma[J]. Expert Opin Ther Targets, 2009, 13(5):523-540.
[13]
Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness[J]. Nature, 2002, 418(6896):426-430.
